The Albanese Government has effectively rejected or obfuscated most of the committee's recommendations, but that does not mean the response has no value or cannot contribute to positive change. Stakeholders must understand the nuance and recognise the real opportunities because these processes never deliver the 'magic bullet'.
A minimalist but entirely predictable response - the opportunities are in the nuance
December 1, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 June
June 26, 2026 - - Podcast -
Arrotex and CStone partner to bring new anti PD-L1 therapy to Australia and New Zealand
June 26, 2026 - - Latest News -
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 - - Latest News -
Guild says pharmacy a solution as AMA flags ambulance ramping crisis
June 26, 2026 - - Latest News -
LENZ and Arrotex partner to bring once daily presbyopia treatment to Australia and New Zealand
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News


